Cancer vaccines, a critical review - Part II

Current Opinion in Investigational Drugs

Volumn 3, Issue 1, 2002, Pages 150-158

  Mitchell, Malcolm S ^a  

^a KARMANOS CANCER INSTITUTE   (United States)

Author keywords

Antigen; Cancer vaccine; Genomics; Superagonists; Vectors

Indexed keywords

ALPHA INTERFERON; ALVAC; ANTIIDIOTYPIC ANTIBODY; BCG VACCINE; CANCER VACCINE; CARCINOEMBRYONIC ANTIGEN; CELECOXIB; CYCLOOXYGENASE 1 INHIBITOR; CYCLOPHOSPHAMIDE; DETOX B; DNA VACCINE; GANGLIOSIDE ANTIGEN; GANGLIOSIDE GM2; GLYCOPROTEIN GP 100; IBUPROFEN; INDOMETACIN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; KEYHOLE LIMPET HEMOCYANIN; M VAX; MELACINE; MELAN A; MELANOMA ANTIGEN; MELANOMA ANTIGEN 1; MELANOMA ANTIGEN 3; MELANOMA VACCINE; MUCIN 1; PEPTIDE; PROSTAGLANDIN SYNTHASE INHIBITOR; QS; QS 21; RITUXIMAB; TELOMERASE; THERATOPE; TUMOR ANTIGEN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIRUS VECTOR; HEMOCYANIN; SIALYL TN ANTIGEN KEYHOLE LIMPET HEMOCYANIN CONJUGATE; SIALYL-TN ANTIGEN-KEYHOLE-LIMPET HEMOCYANIN CONJUGATE;

ADENOCARCINOMA; ADVANCED CANCER; AGONIST; ANTIBODY DETECTION; ANTINEOPLASTIC ACTIVITY; BIOCHEMISTRY; BREAST CANCER; CANCER GENETICS; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CELL LINEAGE; CLINICAL TRIAL; COMBINATORIAL LIBRARY; DENDRITIC CELL; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENTIATION; GENOMICS; HUMAN; IMMUNE RESPONSE; IMMUNODETECTION; IMMUNOGENICITY; IMMUNOREACTIVITY; LYMPHOMA; MELANOMA; META ANALYSIS; MOLECULAR BIOLOGY; NONHUMAN; ONCOGENE NEU; REVIEW; SOLID TUMOR; TUMOR CELL LINE; ANIMAL; GENE VECTOR; IMMUNOLOGY; NEOPLASM;

ANIMAL; ANTIGENS, TUMOR-ASSOCIATED, CARBOHYDRATE; CANCER VACCINES; GENETIC VECTORS; HEMOCYANIN; HUMAN; MELANOMA; NEOPLASMS; ANIMALS; HUMANS;

EID: 0035985657     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (75)

1. A randomised phase II study of sialyl-Tn and DETOX-B adjuvant with or without cyclophosphamide pretreatment for the active specific immunotherapy of breast cancer
2. Evidence of a cellular immune response against sialyl-Tn in breast and ovarian cancer patients after high-dose chemotherapy, stem cell rescue, and immunization with Theratope STn-KLH cancer vaccine
3. Antibodies against mucin-associated sialyl-Tn epitopes correlate with survival of metastatic adenocarcinoma patients undergoing active specific immunotherapy with synthetic STn vaccine
4. Specific major histocompatibility complex-unrestricted recognition of tumor-associated mucins by human cytotoxic T-cells
5. Specific recognition of human tumor associated antigens by non-MHC-restricted CTL
6. Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies
7. Anti-MUC1 class I restricted CTLs in metastatic breast cancer patients immunized with a synthetic MUC1 peptide
8. Identification of an HLA-A11-restricted epitope from the tandem repeat domain of the epithelial tumor antigen mucin
9. HER-2. A potential approach to human breast cancer
10. Immunity to the HER-2/neu oncogenic protein
11. Protection against mammary tumor growth by vaccination with full-length, modified human ErbB-2 DNA
12. Towards a network theory of the immune response
13. Treatment of B-cell lymphomas with anti-idiotype antibodies alone and in combination with α-interferon
14. Targeted anti-cancer therapy using rituximab, a chimaeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin's B-cell lymphoma
15. Active specific immunotherapy in patients with melanoma. A clinical trial with mouse anti-idiotypic monoclonal antibodies elicited with syngeneic anti-high-molecular-weight-melanoma-associated antigen monoclonal antibodies
16. Active specific immunotherapy of metastatic melanoma with an anti-idiotype vaccine: A phase I/II trial of I-Mel-2 plus SAF-m
17. A novel melanoma gene (MG50) encoding the interleukin 1 receptor antagonist and six epitopes recognized by human cytolytic T-lymphocytes
18. Cancer-associated MUC1 mucin inhibits human T-cell proliferation, which is reversible by IL-2
19. Genes coding for tumor rejection antigens: Perspectives for specific immunotherapy
20. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T-cells infiltrating into tumor
21. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T-lymphocytes associated with in vivo tumor regression
22. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells
23. Clinical trials of idiotype-specific vaccine in B-cell lymphomas
24. Linkage of foreign carrier protein to a self-tumor antigen enhances the immunogenicity of a pulsed dendritic cell vaccine
25. Novel gene sequences expressed by human melanoma cells identified by molecular subtraction
26. Assignment of a human melanoma associated gene MG50 (D2S448) to chromosome 2p25.3 by fluorescence in situ hybridization
27. The human interleukin-1 receptor antagonist (IL1RN) gene is located in the chromosome 2q14 region
28. Probing degeneracy in T-cell recognition using peptide combinatorial libraries
29. Induction of cytotoxic T-cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells
30. Approaches to augmenting the IgG antibody response to melanoma ganglioside vaccines
31. Improved survival in stage III melanoma patients with GM2 antibodies: A randomized trial of adjuvant vaccination with GM2 ganglioside
32. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684
33. Generation of human cytotoxic T-cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine
34. Diversified prime and boost protocols using recombinant vaccinia virus and recombinant non-replicating avian pox virus to enhance T-cell immunity and antitumor responses
35. Phase I clinical trial of a recombinant canarypoxvirus (ALVAC) vaccine expressing human carcinoembryonic antigen and the B7.1 co-stimulatory molecule
36. Strategies in the development of recombinant vaccines for colon cancer
37. Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens
38. Transduction of CD34+ cells by a vesicular stomach virus protein G (VSV-G) pseudotyped HIV-1 vector. Stable gene expression in progeny cells, including dendritic cells
39. Recombinant viruses as a tool for therapeutic vaccination against human cancers
40. Immunogenicity and antitumor activity of a liposomal MUC1 peptide-based vaccine
41. Liposomal formulations of synthetic MUC1 peptides: Effects of encapsulation versus surface display of peptides on immune responses
42. Rapid induction of primary human CD4+ and CD8+ T-cell responses against cancer-associated MUC1 peptide epitopes
43. Vaccination of rhesus monkeys with synthetic peptide in a fusogenic proteoliposome elicits simian immunodeficiency virus- specific CD8+ cytotoxic T-lymphocytes
44. Cytotoxicity of anti-c-erbB-2 immunoliposomes containing doxorubicin on human cancer cells
45. Delivery of MUC1 mucin peptide by poly(d,I-lactic-co-glycolic acid) microspheres induces type 1 T-helper immune responses
46. Epitope-specific cytotoxic T-lymphocyte induction by minigene DNA immunization
47. Utilization of MHC class I transgenic mice for development of minigene DNA vaccines encoding multiple HLA-restricted CTL epitopes
48. Protective immunity against human carcinoembryonic antigen (CEA) induced by an oral DNA vaccine in CEA-transgenic mice
49. Engineering enhancement of immune responses to DNA-based vaccines in a prostate cancer model in rhesus macaques through the use of cytokine gene adjuvants
50. DNA vaccines targeting dendritic cells for the immunotherapy of cancer
51. Defined flanking spacers and enhanced proteolysis is essential for eradication of established tumors by an epitope string DNA vaccine
52. Genetic adjuvants for DNA vaccines
53. Modulation of cellular and humoral immune responses to a multiepitopic HIV-1 DNA vaccine by interleukin-18 DNA immunization/viral protein boost
54. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells
55. Mature dendritic cells pulsed with freeze-thaw cell lysates define an effective in vitro vaccine designed to elicit EBV-specific CD4(+) and CD8(+) T-lymphocyte responses
56. Regression of tumors in mice vaccinated with professional antigen-presenting cells pulsed with tumor extracts
57. Use of autologous dendritic cells loaded with apoptotic LCL for ex vivo generation of specific CTL from the PBMC of EBV(-) individuals
58. Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells
59. Induction of polyclonal prostate cancer-specific CTL using dendritic cells transfected with amplified tumor RNA
60. Mage-3 and influenza-matrix peptide-specific cytotoxic T-cells are inducible in terminal stage HLA-A2.1+ melanoma patients by mature monocyte-derived dendritic cells
61. Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells
62. Synthetic insertion signal sequences enhance MHC Class I presentation of a peptide from the melanoma antigen MART-1
63. Cancer vaccines: Novel approaches and new promise
64. Generation of tissue-specific and promiscuous HLA ligand databases using DNA microarrays and virtual HLA class II matrices
65. Consensus motifs and peptide ligands of MHC class I molecules
66. Exploring immunological specificity using synthetic peptide combinatorial libraries
67. Methyl inosine monophosphate: A potential immunotherapeutic for early human immunodeficiency virus (HIV) infection
68. Potentiation of human cell-mediated and humoral immunity by low-dose cyclophosphamide
69. Effectiveness and tolerability of low-dose cyclophosphamide and low-dose intravenous interleukin-2 in disseminated melanoma
70. Active specific immunotherapy of melanoma: Phase I trial of allogeneic melanoma lysates and a novel adjuvant
71. The HLA crossroad in tumor immunology
72. Impediments to successful immunotherapy
73. Tumor escape from immune recognition: Loss of HLA-A2 melanoma cell surface expression is associated with a complex rearrangement of the short arm of chromosome 6
74. Relapse in the central nervous system in melanoma patients successfully treated with biomodulators
75. A personal (biased) perspective on cancer 'vaccines'